No Data
No Data
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Tecan Group AG (OtherTCHBF) and Avidity Biosciences (RNA)
Avidity Biosciences Plans to Submit First Biologics License Application This Year
Express News | Avidity Biosciences: Accelerated Approval Path Confirmed for Del-Zota; Bla Submission Planned for Year End 2025
Press Release: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
No Data